IL283231B1 - DPEP-1 binding factors and methods of use - Google Patents

DPEP-1 binding factors and methods of use

Info

Publication number
IL283231B1
IL283231B1 IL283231A IL28323121A IL283231B1 IL 283231 B1 IL283231 B1 IL 283231B1 IL 283231 A IL283231 A IL 283231A IL 28323121 A IL28323121 A IL 28323121A IL 283231 B1 IL283231 B1 IL 283231B1
Authority
IL
Israel
Prior art keywords
dpep
methods
binding agents
binding
agents
Prior art date
Application number
IL283231A
Other languages
English (en)
Hebrew (he)
Other versions
IL283231A (en
Original Assignee
Arch Biopartners Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arch Biopartners Inc filed Critical Arch Biopartners Inc
Publication of IL283231A publication Critical patent/IL283231A/en
Publication of IL283231B1 publication Critical patent/IL283231B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL283231A 2018-11-30 2021-05-18 DPEP-1 binding factors and methods of use IL283231B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862773733P 2018-11-30 2018-11-30
PCT/IB2019/001289 WO2020109864A1 (en) 2018-11-30 2019-12-02 Dpep-1 binding agents and methods of use

Publications (2)

Publication Number Publication Date
IL283231A IL283231A (en) 2021-07-29
IL283231B1 true IL283231B1 (en) 2026-03-01

Family

ID=70853301

Family Applications (1)

Application Number Title Priority Date Filing Date
IL283231A IL283231B1 (en) 2018-11-30 2021-05-18 DPEP-1 binding factors and methods of use

Country Status (7)

Country Link
US (3) US11286278B2 (https=)
EP (1) EP3887390A4 (https=)
JP (2) JP7535514B2 (https=)
AU (1) AU2019386379B2 (https=)
CA (1) CA3121300A1 (https=)
IL (1) IL283231B1 (https=)
WO (1) WO2020109864A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7535514B2 (ja) * 2018-11-30 2024-08-16 アーチ バイオパートナーズ， インコーポレイテッド Ｄｐｅｐ－１結合剤および使用の方法
EP4320167A4 (en) * 2021-04-08 2025-08-06 Nat Res Council Canada DPEP-1 BINDING AGENTS AND METHODS OF USE THEREOF
EP4574146A1 (en) 2023-12-18 2025-06-25 Telara Pharma S.L. Dhp-i inhibitors for use as neuroprotectants and in the treatment of neuroinflammatory diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015120536A1 (en) * 2014-02-13 2015-08-20 Arch Cancer Therapeutics, Inc. Peptides that block leukocyte recruitment and methods of use
WO2017025802A1 (en) * 2015-08-11 2017-02-16 Arch Biopartners, Inc. Dpep-1 binding compositions and methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223558B2 (en) * 2001-07-11 2007-05-29 Bristol-Myers Squibb Company Polynucleotides encoding three novel human cell surface proteins with leucine rich repeats and immunologobulin folds, BGS2, 3, and 4 and variants thereof
WO2007081751A2 (en) * 2006-01-05 2007-07-19 The Johns Hopkins University Compositions and methods for the treatment of cancer
EP2561359A1 (en) * 2010-04-20 2013-02-27 Addex Pharma SA Chimeric polypeptides useful in proximal and dynamic high-throughput screening methods
WO2012112420A1 (en) * 2011-02-14 2012-08-23 Allergan, Inc. Treatments using psma ligand endopeptidases
EP3519443A4 (en) * 2016-09-30 2020-06-10 Baylor College of Medicine CHIMERIC ANTIGEN RECEPTOR THERAPY WITH REDUCED CYTOTOXICITY FOR VIRAL DISEASE
JP2019529499A (ja) * 2016-09-30 2019-10-17 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ 組織指向性発現を用いた抗体ベースの遺伝子治療
JP7535514B2 (ja) * 2018-11-30 2024-08-16 アーチ バイオパートナーズ， インコーポレイテッド Ｄｐｅｐ－１結合剤および使用の方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015120536A1 (en) * 2014-02-13 2015-08-20 Arch Cancer Therapeutics, Inc. Peptides that block leukocyte recruitment and methods of use
WO2017025802A1 (en) * 2015-08-11 2017-02-16 Arch Biopartners, Inc. Dpep-1 binding compositions and methods of use

Also Published As

Publication number Publication date
EP3887390A4 (en) 2022-11-23
JP2024028553A (ja) 2024-03-04
AU2019386379B2 (en) 2025-05-22
US20220251140A1 (en) 2022-08-11
CA3121300A1 (en) 2020-06-04
AU2019386379A1 (en) 2021-07-15
JP2022509258A (ja) 2022-01-20
JP7535514B2 (ja) 2024-08-16
US20200223888A1 (en) 2020-07-16
IL283231A (en) 2021-07-29
US11286278B2 (en) 2022-03-29
EP3887390A1 (en) 2021-10-06
US20250333443A1 (en) 2025-10-30
WO2020109864A1 (en) 2020-06-04

Similar Documents

Publication Publication Date Title
IL276687A (en) Trialkyne coupling agents and methods of using them
IL276731A (en) Antibodies against CD73 and methods of using them
IL278821A (en) Anti-SIRPA antibodies and methods of using them
SG11202001063QA (en) Clec9a binding agents and use thereof
SG11202010909RA (en) Anti-msr1 antibodies and methods of use thereof
ZA202300348B (en) Anti-sortilin antibodies and methods of use thereof
IL261666A (en) Related proteins and methods of using them
IL279648A (en) Anti-SIRP-in-cell 1 antibodies and methods of using them
IL282350A (en) Bernani-RGMC inhibitors and their use
IL279475A (en) Actonucleotidase inhibitors and methods of using them
SG11202102053VA (en) Pyridazinones and methods of use thereof
IL283387A (en) Diarylhydantoin compounds and methods of use thereof
IL276135A (en) Preparations and methods of use
IL277212A (en) Anti-KLK5 antibodies and methods of use
ZA202100780B (en) Bismuth-thiol compositions and methods of use
IL280338A (en) Anti-SIGLEC-5 antibodies and methods of using them
IL283884A (en) Antibodies against il-36 and methods of using them
IL276053A (en) Therapeutic Gard and methods of its use
IL279227A (en) Anti-SIGLEC-7 antibodies and methods of using them
EP3749691A4 (en) ANGPTL8 LIAISON AGENTS AND THEIR METHODS OF USE
IL283231A (en) dpep-1 binding factors and methods of use
GB2589398B (en) Compounds and methods of use
HK40045754A (en) B7-h7-binding agents and methods of use thereof
GB201908573D0 (en) Compounds and methods of use